Event - From Innovation to Impact: Resolving Pinch Points in Cell and Gene Therapies, 23 July

On Wednesday 23 July, we were delighted to host our panel discussion and networking event "From Innovation to Impact: Resolving Pinch Points in Cell and Gene Therapies", featuring an incredible line-up of of speakers from across the cell and gene therapy ecosystem:

• Jonathan Tobin - Partner at Brandon Capital
• Prof. Chris Molloy - Life Sciences Leader at the Medicines Discovery Catapult
• Matthew Garner - former Head of Intellectual Property at the Cell and Gene Therapy Catapult
• Dr Katy Newton - Chief Scientific Officer at MFX
• Sean O’Farrell - Senior Consultant at Dark Horse Consulting Group

The evening began with a warm welcome from Anna Mudge, followed by an hour long panel discussion moderated by Adam Gregory.

The panel session provided an opportunity to explore challenges within the cell and gene therapy field, while at the same time acknowledging the continued hope and optimism for such life-changing therapies. Topics included what makes a therapy compelling to investors, how organisations can benefit from collaborating with Catapults, bottlenecks in process development, tips on dealing with regulators and hopes for the future. 

Following the panel, guests stayed on for drinks, canapés, and informal networking. It was a fantastic opportunity for attendees to continue the conversations sparked during the discussion, meet others working across different areas of the sector, and forge new connections.

We're incredibly grateful to our panellists for their invaluable expertise and for taking time out of their busy schedules. It was wonderful to have so many engaged participants. We thank everyone who joined us!

Left to right: Anna Mudge, Sean O’Farrell, Prof. Chris Molloy, Jonathan Tobin, Matthew Garner, Dr Katy Newton, Adam Gregory, Laura Carney